Pharmaceutics客座编辑，并长期担任特邀审稿人为Journal of Hematology & Oncology, Advanced Functional Materials, Small，Journal of Controlled Release, Acta Biomaterialia, Molecular Therapy, Acta Pharmaceutica Sinica B, Journal of Nanobiotechnology, Advanced NanoBiomed Research等顶级期刊杂志进行同行评审。

主要研究课题：

1. 四川省高层次青年人才项目，生物大分子药物的口服递送研究，2024-2026，50万，主持

2. 四川省重点研发计划项目（国际合作），非侵入性多靶点调控内源性肠道激素释放的作用机制和应用研究，2024YFHZ0326，2024-2025，20万，主持

3. 国家自然科学基金面上项目，肠道内源性激素分泌调控在糖脂代谢中的作用和机制研究，82370860，2024-2027，48万，主持

4. 国家自然科学基金优秀青年科学基金项目（海外），代谢性疾病和口服智能给药系统，2023-2026，200万，主持

5. 四川大学高层次引进人才科研启动资助项目，2024-2026，200万，主持

6. 四川大学华西医院高层次引进人才科研启动资助项目，2023-2027，800万，主持

7. 比利时国家科学基金青年项目（FNRS-CR），Oral smart drug delivery systems-hormones，40010880，2022-2025，122万，主持

8. 比利时地区政府卓越杰出博士后项目，Unravelling the biological mechanism behind the incretin effect exerted by lipid nanocarriers via oral route，SOR/2020/479041，2020-2022，36.6万，主持

代表论著：

1. Cheng Chen, Ana Beloqui*, Yining Xu*. Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease. Advanced Drug Delivery Reviews, 203 (2023): 115117. (IF: 17.873)

2. Valentina Marotti1, Yining Xu1, Cécilia Bohns Michalowski1, Wunan Zhang, Inês Domingues, Hafsa Ameraoui, Tom G. Moreels, Pieter Baatsen, Matthias Van Hul, Giulio G. Muccioli, Patrice D. Cani, Mireille Alhouayek, Alessio Malfanti, Ana Beloqui*. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioactive Materials, (32)2024: 206-221. (共同一作) (IF: 18.9)

3. Yining Xu, Thibaut Fourniols1, Yasmine Labrak1, Véronique Préat, Ana Beloqui*, Anne des Rieux*. Surface Modification of Lipid-Based Nanoparticles. ACS NANO, 16 (2022) 7168-7196. (IF: 18.027)

4. Yining Xu, Neha Shrestha1, Véronique Préat*, Ana Beloqui*. An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers. Advanced Drug Delivery Reviews, 175 (2021): 1137952. (IF: 17.873)

5. Yining Xu, Cecilia Bohns Michalowsk, and Ana Beloqui*. Advances in lipid carriers for drug delivery to the gastrointestinal tract. Current Opinion in Colloids & Interface Science, 52 (2021):101414. (IF: 8.209)

6. Yining Xu, Herlinde De Keersmaecker, Kevin Braeckmans, Stefaan De Smedt, Patrice D. Cani, Véronique Préat, Ana Beloqui*. Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment. Biomaterials, 255 (2020) 120209. (IF: 15.304)

7. Yining Xu, Matthias van Hul, Francesco Suriano, Véronique Préat, Patrice D. Cani*, Ana Beloqui*. Novel strategy for oral peptide delivery in incretin-based diabetes treatment. Gut, 69 (2020) 911-919. (IF: 31.793) (入选Gut高影响论文)

8. Yining Xu, Neha Shrestha, Véronique Préat, Ana Beloqui*. Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. Journal of Controlled Release, 322 (2020) 486-508. (IF: 11.467)

9. Yining Xu, Yaxian Zheng1, Lei Wu, Xi Zhu, Zhirong Zhang, Yuan Huang*. A novel solid lipid nanoparticle with endosomal escaping function for oral insulin delivery. ACS Applied Materials & Interfaces, 10 (2018) 9315-9324. (IF: 10.383)

10. Yining Xu, Dario Carradori, Mireille Alhouayek, Giulio G. Muccioli, Patrice D. Cani, Véronique Préat *, Ana Beloqui*. Size effect on lipid nanocapsules-mediated GLP-1 secretion from enteroendocrine L cells. Molecular Pharmaceutics, 15 (2018) 108-115. (IF: 5.364)

11. Yining Xu, Juan Xu, Wei Shan, Min Liu, Yi Cui, Lian Li, Chong Liu, Yuan Huang*. The transport mechanism of integrin αvβ3 receptor targeting nanoparticles in Caco-2 cells. International Journal of Pharmaceutics, 500 (2016) 42-53. (IF: 6.510)

12. Peiwen Zhang1, Yining Xu1, Xi Zhu, Yuan Huang*. Goblet Cell Targeting Nanoparticle containing Drug-loaded Micelle Cores for Oral Delivery of Insulin. International Journal of Pharmaceutics, 496 (2015) 993-1005. (共同一作) (IF: 6.510)